Rigaku Joins Two Partners in Establishing RIGAKU/JEOL-iCeMS Innovation Core and Concluding a Cooperation Agreement
4.9.2025 17:00:00 EEST | Business Wire | Press release
On September 4, 2025, Rigaku Corporation, a global solution partner in X-ray analytical systems and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President & CEO: Jun Kawakami; hereinafter “Rigaku”); Kyoto University (Main campus: Kyoto; Nagahiro Minato, President; hereinafter “Kyoto University”); and JEOL Ltd. (headquarters: Akishima, Tokyo; President & CEO: Izumi Oi, hereinafter “JEOL”) concluded an agreement to establish an organization for open innovation. The purpose of this initiative is to leverage each other’s strengths, conduct joint research and development and cultivate skilled personnel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250904601877/en/
RIGAKU/JEOL-iCeMS Innovation Core
The newly established RIGAKU/JEOL-iCeMS Innovation Core is a joint research facility founded within the Analysis Center of the Institute for Integrated Cell-Material Sciences (Kyoto University iCeMS).
RIGAKU/JEOL-iCeMS Innovation Core will apply innovative methods of molecular-structure analysis, centering on electron-beam diffraction of nanocrystals. In particular, the joint research facility will furnish a measurement environment to accelerate the search for functions in new materials, using tools such as XtaLAB Synergy-ED. (XtaLAB Synergy-ED is a radically new electron diffraction and integration platform that integrates Rigaku’s monocrystal X-ray structural-analysis technology with JEOL’s transmission electron microscopy technology.)
In this way RIGAKU/JEOL-iCeMS Innovation Core aims to advance basic research, return research results to society and cultivate skilled personnel, thereby contributing to innovation through academic-industrial partnership.
RIGAKU/JEOL-iCeMS Innovation Core is an R&D facility dedicated to the advancement of material science through open innovation. Focusing on nanocrystal materials discovered through partnership between academia and industry, RIGAKU/JEOL-iCeMS Innovation Core aims to build a platform to elucidate the relationships between structure and function of these materials and develop applications for them.
Overview of the agreement and joint research facility |
Agreement period: From September 4, 2025 to March 31, 2028 |
Contract renewal possible |
Overview of joint research facility: RIGAKU/JEOL-iCeMS Innovation Core |
Joint research facility founded within iCeMS Analysis Center, Kyoto University |
Comments
Jun Kawakami
President & CEO, Rigaku
I am delighted that Rigaku was able to join Kyoto University and JEOL in establishing this new research and development base. Since its foundation, Rigaku has proudly contributed to scientific progress through advancements in structural-analytical technology. Through the use of electron diffraction of nanocrystals, RIGAKU/JEOL-iCeMS Innovation Core will accelerate the development of this technology and research in its applications. We look forward to returning the knowledge obtained through this academic-industrial partnership to the broader society and using it to develop the next generation of skilled personnel on whom the future depends.
Nagahiro Minato
President, Kyoto University
With the foundation of RIGAKU/JEOL-iCeMS Innovation Core, these three partners—Rigaku, JEOL and Kyoto University—have joined hands to advance leading-edge research and development through open innovation. This initiative is one of great importance, as it dovetails with the University’s orientation to ally with analytical-device manufacturers on the concept of a core facility for Kyoto University under the plan for the University for International Research Excellence. We have high expectations that this effort will lead to strengthened research, innovation and development of outstanding personnel. Moreover, the results of this project will underpin the scientific, technological and industrial foundations not only of the three partners but of Japan in general, and will support breakthroughs in finding solutions to issues confronting society. Kyoto University will expend every effort to ensure the success of RIGAKU/JEOL-iCeMS Innovation Core.
Izumi Oi
President & CEO, JEOL
The establishment of RIGAKU/JEOL-iCeMS Innovation Core in partnership with Kyoto University and Rigaku is a vital initiative toward equipping society with revolutionary structural-analytical technologies. By developing electron diffractometers applying transmission electron microscopy technology, JEOL looks forward to advancing the structural analysis of nanocrystals and accelerating the elucidation of functions of new materials. Through the technological innovations advanced through these efforts and the products and technologies they generate, RIGAKU/JEOL-iCeMS Innovation Core will support applied research in a wide range of fields, including life sciences, the environment, energy and more, contributing to scientific progress and social development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250904601877/en/
Contacts
Press Contact:
Sawa Himeno
Head of Communications Dept., Rigaku Holdings Corporation
prad@rigaku.co.jp
Tel: +81 90 6331 9843
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom